Comparison of warfarin with direct oral anticoagulants for thromboembolic prophylaxis after catheter ablation of ventricular tachycardia
Journal of Cardiovascular Electrophysiology · 2023
DOI: 10.1111/jce.15827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2023. Verfasst von Amrish Deshmukh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Thromboembolism, Tachycardia, Ventricular, Catheter Ablation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Thromboembolic events after catheter ablation of ventricular tachycardia (VT) can result in significant morbidity. Thromboembolic prophylaxis after catheter ablation can be achieved by the use of antiplatelet agents, vitamin K antagonists, or direct oral anticoagulants (DOACs). The relative safety and efficacy of these modes of prophylaxis are uncertain. We sought to compare the outcomes of patients who received warfarin or DOACs for thromboembolic prophylaxis after catheter ablation of VT. Methods and Results Anticoagulation with DOACS was started after left ventricular VT ablation in a series of 42 consecutive patients with structural heart disease (67 ± 11 years, 3 women, ejection fraction 32 ± 14%). Duration of hospital stay, bleeding episodes, and thromboembolic events were compared to a historic consecutive group of patients ( n = 38, 65 ± 13 years, 14 women, ejection fraction 36 ± 13%) in whom anticoagulation with a formerly described protocol of heparin and vitamin K antagonist was used after VT ablation procedures. Hospital stay was significantly shorter in the group where DOACs were used as compared to vitamin K antagonists (3.3 ± 1.8 vs. 5.0 ± 2.5 days postablation; p = 0.001) without an increase of bleeding or thromboembolic events.
Conclusion
Anticoagulation with DOACs is safe and shortens hospital stay in patients with structural heart disease undergoing left ventricular VT ablation procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Amrish Deshmukh, Michael Ghannam, Jackson Liang, Frank Bogun
Zitieren
APA
Deshmukh, A., Gunda, S., Siontis, K. C., Ghannam, M., Liang, J., Latchamsetty, R., Jongnarangsin, K., Morady, F., & Bogun, F. (2023). Comparison of warfarin with direct oral anticoagulants for thromboembolic prophylaxis after catheter ablation of ventricular tachycardia. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.15827
Vancouver
Deshmukh A, Gunda S, Siontis KC, Ghannam M, Liang J, Latchamsetty R, et al. Comparison of warfarin with direct oral anticoagulants for thromboembolic prophylaxis after catheter ablation of ventricular tachycardia. Journal of Cardiovascular Electrophysiology. 2023. doi:10.1111/jce.15827
BibTeX
@article{Deshmukh2023,
author = {Deshmukh, Amrish and Gunda, Sampath and Siontis, Konstantinos C and Ghannam, Michael and Liang, Jackson and Latchamsetty, Rakesh and Jongnarangsin, Krit and Morady, Fred and Bogun, Frank},
title = {Comparison of warfarin with direct oral anticoagulants for thromboembolic prophylaxis after catheter ablation of ventricular tachycardia},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2023},
doi = {10.1111/jce.15827}
}
EUVIMED